BrainStorm Cell Therapeutics

Brainstorm Cell Therapeutics placed common shares at USD 0.60 per share and accompanying warrants with 120% coverage and an exercise price of USD 1.00, with financing to occur in up to eight tranches. With the transaction, capital raised in February increases to a total of USD 2.0 million. The company intends to use the proceeds as working capital and to support regulatory and clinical development initiatives. The stock has recently risen, with a market capitalization of around USD 6.88 million; the company also received a Notice of Allowance for an exosome patent and is advancing development of the NurOwn and MSC‑NTF programs. » Plus sur de.investing.com

Brainstorm Cell has completed a private placement of US$1 million; the price was set at US$0.60 per common share, a premium to the US$0.54 closing price on 9 February. The financing includes warrants with 120% coverage and a five‑year term at an exercise price of US$1.00; proceeds will be paid in two tranches (first tranche of US$500,000 already received). Proceeds are intended to fund regulatory initiatives, advance payments for the planned phase‑3b study of NurOwn for ALS and general corporate purposes; the company has a market capitalization of US$5.78 million and a strained liquidity position (current ratio 0.06). » Plus sur de.investing.com

BrainStorm Cell Therapeutics is being delisted from NASDAQ due to not meeting equity requirements and will shift trading of its shares to the OTCQB Venture Market. Despite financial difficulties and a significant drop in share price, the company emphasizes that the delisting will not affect ongoing research and development activities, particularly the planned Phase 3b study for ALS therapy. BrainStorm continues to seek strategic financing opportunities and partnerships to advance its projects. » Plus sur de.investing.com